sputnik v russian спутник v brand name rdif gamcovidvac russian гамковидвак name legally registered adenovirus viral vector vaccine developed gamaleya research institute epidemiology microbiology russia worlds first registered combination vector vaccine prevention registered august russian ministry gamcovidvac initially approved distribution russia countries april preliminary results phase studies eventually published september approval early august gamcovidvac met criticism mass media discussions scientific community whether approval justified absence robust scientific research confirming safety largescale brazilian study dec may confirmed effectiveness safety ie sinopharm emergency massdistribution vaccine began december countries including russia argentina belarus hungary serbia pakistan limited quantities philippines limited quantities united arab emirates sputnik v currently registered certified however april less people vaccinated worldwide taken sputnik v early result russian invasion ukraine united states countries placed rdif list sanctioned russian entities significantly reducing sputnik vs future commercial gamcovidvac vaccine available two forms frozen vaccine storage liquid vaccine storage produced little addition main vaccine vaccines derivatives registered gamcovidvaclyo russian гамковидваклио data use sputnik light russian спутник лайт used revaccination well vaccination foreigners russia gamcovidvacm russian гамковидвакм vaccination adolescents years vaccine formulated two ways readytouse solution water frozen common homefreezer storage temperature lower freezedried lyophlilized powder gamcovidvaclyo stored freezedried powder must reconstituted sterile water lyophilized formulation gamcovidvac similar smallpox vaccine circumventing need continuous colder chain coldchain storage required moderna vaccines allowing transportation remote locations reduced risk vaccine first dose based administered first day second dose based administered day boost immune doses administered deltoid muscle sputnik light registered singledose vaccine consisting first dose sputnik v intended areas acute outbreaks used third booster dose received sputnik v least months august developers sputnik v vaccine offered sputnik light vaccine pfizer trial delta effectiveness vaccines vaccine determined mass vaccination realworld setting clinical trials assessment well vaccine protects people outcomes infection symptomatic illness hospitalization death effectiveness evaluated outside clinical trials contrast evaluate efficacy vaccine generally considered effective estimate lower limit confidence effectiveness generally expected slowly decrease august preliminary version casecontrol study indicated unadjusted symptomatic disease authors expected adjusting age sex would increase estimate citing increase adjusting data effectiveness hospitalizationa largescale study buenos aires december may participants aged older received spunik v vaccine sinopharm bibp vaccine observed overall efficacy ci deaths study noted three vaccines showed similar effectiveness death effectiveness infection similar oxfordastrazeneca vaccine greater sinopharm bibp largescale study conducted study compared adults vaccinated different vaccines unvaccinated adults december september results follows vaccine efficacy vaccine vaccine evaluated controlled clinical trials estimate many people received vaccine got disease compared many people got placebo outcome february interim analysis moscow trial published lancet reporting efficacy ci second dose age groups unusual side age group years older reported efficacy may group biostatisticians russia us france italy netherlands questioned efficacy results correspondence lancet highlighting data discrepancies substandard reporting apparent errors numerical inconsistencies unlikely homogeneity vaccine efficacy across age authors responded saying provided regulatory authorities data necessary obtaining approval data included paper enough readers confirm reported vaccine efficacy also addressed protocol queries said numerical inconsistencies simple typing errors formally june group biostatisticians australia singapore published paper suggesting almost identical efficacy every age group lancet paper unlikely occur genuine experimental group called thorough investigation lancet article well immediate release anonymized individual patient data unbiased statistical expert suggested article retracted lancet group recognized concerns validity data published article invited authors article respond latest side effects mostly mild similar adenovirus vector vaccines oxfordastrazeneca janssen vaccines however unlike oxfordastrazeneca janssen vaccines pfizer evidence suggest risk vaccineinduced immune thrombotic although report argentina published new england journal medicine described fatal vaccineinduced thrombocytopenia thrombosis young woman receipt gamcovidvac viral vector vaccine based two recombinant replicationdefective human adenoviruses serotype serotype replicated hek cells viruses contain gene encodes fulllength spike protein stimulate immune adenoviral expression spike protein also used two vaccines one janssen vaccine utilizes viral vector based human virus vaccine cell line used replicate vector another one vaccine uses chimpanzee adenovirus vector oxfordastrazeneca gamcovidvac vaccines producer cells production nonreplicating adenoviral vectors obtained hek cell dose gamcovidvac contains virus modified remove gene prevent replication outside hek production vaccine propagate adenoviral vectors gene deleted hek cells used express several adenoviral genes including however although rare homologous recombination inserted cellular sequence vector sequence restore replication capacity less replicating adenovirus particles per dose ingredients excipients quantitatively qualitatively two components ingredients included large quantities adenoviruses produced hek cells gene necessary viral rarely acquire gene hek cells restoring ability gamaleya set acceptable limit replicating virus particles per vaccine dose quality control documents state tested batches contain less replicating virus particles per production frozen liquid formulation developed largescale use cheaper easier manufacture production freezedried formulation takes much time resources although convenient storage transportation developed vaccine delivery hardtoreach regions russia according russian media mass production gamcovidvac launched august moment russian federation already received applications countries supply billion doses vaccine three facilities able produce million doses per month potential doubling capacity winter end gamaleya research institutes production according interview organizations spokesperson planned produce million march russian direct investment fund rdif licensed production india china south korea brazil eu rdif signed production agreements end march rdif anticipates million doses manufactured russia less agreement production million doses vaccine india made dr reddys laboratories january submitted midstage trial data indian regulator recommended moving onto latestage rdif announced plans sell million doses india million uzbekistan million mexico well million nepal india first dose sputnik v vaccine administered may argentina became first latin american country produce largescale production started june december million doses manufactured mostly million february result russian invasion ukraine united states placed rdif chief executive list sanctioned russian entities european union ukraine united kingdom australia followed later february significantly reduces vaccines future commercial gamcovidvac vaccine developed cellular microbiologists team governmentbacked gamaleya research institute epidemiology microbiology group led md ras associate member denis logunov also worked vaccines ebolavirus merscoronaviruscitation needed may gamaleya research institute epidemiology microbiology announced developed vaccine without serious side effects august phases ii two clinical trials involving patients completed one used formulation later obtained marketing authorization limited vaccine given trade name sputnik v worlds first artificial preclinical clinical trials participants received one two doses gamcovidvac vaccine produced antibodies spike protein including potent neutralizing antibodies inactivate viral august russian minister health mikhail murashko announced government briefing participation president vladimir putin regulatory approval vaccine widespread use state registration vaccine carried conditionally postmarketing measures according decree government russian federation registration certificate vaccine stated could used widely russia january may provided small number citizens vulnerable groups medical staff elderly according ministry health license register number issued august russian ministry health although announcement made even vaccine candidate entered phase iii trials practice marketing authorization conditions also exists august certificate issued lyophilized formulation june developers announced developed tested nasal vaccine children aged side effects found expected release september phase safety trial began june september data participants phase trial published indicating preliminary evidence safety immune results challenged international vaccine scientists incomplete suspicious unreliable identical data reported many trial authors responded small sample size nine measured results titration could take discrete values coupled observation values tended reach plateau three four weeks contend unlikely several participants would show identical results days early november israel hadassah medical center directorgeneral zeev rotstein stated hadassahs branch moscows skolkovo innovation center collaborating phase iii clinical ongoing phase iii study randomised doubleblind placebocontrolled multicentre clinical trial involving volunteers moscow scheduled run may phase iii clinical studies also conducted april indias health ministry said drug regulator found safety immunogenicity data local trial sputnik v coronavirus vaccine comparable latestage trial done may study researchers national university córdoba argentina found vaccine produced antibodies capable neutralizing gamma study argentina found neutralization maintained alpha lambda reduced gamma degree reduction however necessarily imply reduced small study serum samples found antibodies vaccine effectively neutralize alpha variant moderately reduced neutralization substitution median fold reduction however neutralization beta variant markedly reduced median fold august british american officials stated gamcovidvac vaccine would likely rejected due concerns normally rigorous process vaccine clinical testing december belarus argentina granted emergency use authorization vectorbased january hungary became first european union country register shot emergency use well united arab emirates persian gulf january russian authorities applied registration sputnik v european union according february european medicines agency ema said received application rolling review marketing authorisation vaccine developers expressed interest vaccine considered rolling review emas human medicines committee chmp ema pandemic task force covidetf need give agreement first developers submit application initiation rolling review march committee medicinal products human use chmp ema started rolling review sputnik eu applicant rpharm germany june reuters reported approval sputnik v delayed least september necessary clinical data submitted june sputnik v rolling review process ema marketing authorisation application submitted emergency use also authorized algeria bolivia serbia palestinian january iran approved vaccine foreign minister mohammad javad zarif saying country hopes begin purchases start joint production shot near future supreme leader ayatollah ali khamenei banned government importing vaccines united states united czech republic also considering buying sputnik v prime minister andrej babis dismissed minister health jan blatný loud opponent use sputnik march emas human medicines committee chmp started rolling review sputnik v gamcovidvac vaccine developed russias gamaleya national centre epidemiology asked prospect austria giving sputnik v approval european countries chose ema management board chair christa wirthumerhoche pointed fact yet sufficient safety data already given vaccine could sputnik v market future weve examined necessary data said adding vaccine needed match european criteria quality control march german regional leaders including state premiers mayor berlin called swift approval russian vaccine european medicines agency counteract acute shortages effective vaccines europe german medical experts recommended approval also consider sputnik vaccine clever highly march philippine food drug administration granted emergency use authorization sputnik v fourth vaccine given authorization philippine government planned buy million doses april india approved use sputnik v vaccine emergency use based strong immunogenicity april countries granted sputnik v emergency use april bangladesh approved use sputnik v vaccine emergency april turkey albania approved use sputnik v vaccine emergency march slovakia bought million doses sputnik v vaccine slovakia received first batch expected receive another doses march april another million doses set arrive may april slovakias drug regulator said sputnik v vaccine received characteristics properties version endorsed slovak state institute drug control stated sputnik v yet approved use first doses received march different product currently reviewed ema well vaccine used studies published lancet producers failed reply requests documentation approximately data supplied even repeated requests due inconsistencies possible review safety efficacy russian direct investment fund replied slovakian laboratory tested vaccine certified eu slovak prime minister igor matovič resigned march due political crisis started order sputnik v april rdif asked return delivered first batch vaccine due multiple contract april slovak ministry health published sputnik v according contract rdif seller liable adverse events following administering vaccine according slovak lawyers contract explicitly disadvantageous may russian direct investment fund sent letter denník n newspaper requesting removal statements drug regulator calling unsubstantiated false fake rdif threatened newspaper legal action didnt comply demand newspapers editors samples sent eucertified laboratory hungary stated results slovakian government approved vaccine announced vaccination sputnik v would begin june despite negative review slovakias drug vaccinations started without significant interest sputnik v slovakia plans order new plans sell donate unused vaccines balkans registrations vaccination closed june july doses vaccine first batch shipped back temporary government approval sputnik v expired august total people purchase sputnik v led political crisis contributed fall igor matovičs cabinet investigated slovak police force investigation levered marek krajčí violation law found october april brazilian health regulator anvisa rejected use sputnik v alleging lack consistent reliable data presence replicating adenovirus vaccine rdif sputnik vs official twitter account said decision may politically motivated pointing recent report united states government tried persuade brazil reject vaccine several brazilian states north northeast regions already signed contracts acquisition million anvisa attributed decision number issues samples provided gamaleya april developers sputnik v said anvisa admitted testing sputnik v would sue anvisa brazil defamation press conference anvisa officials said gamaleyas documents indicated multiple times presence replicationcompetent adenoviruses rcas ready vaccine batches specifications accepted level rcas times greater regulatory threshold anvisa presented video meeting representatives russia brazil asked presence rcas representative russia reported problems cells said vaccine could redeveloped would take long developers instead chose continue research imposing acceptable level virologist angela rasmussen described problem quality control issue important healthy people adenoviruses important pathogens added could produce serious adverse effects immunocompromised medicinal chemist derek lowe commented presence replicating adenoviruses unlikely cause major problems completely unnecessary risk certainly harm people providing product different one described studies undermines credibility manufacturing quality control adding posts official sputnik v twitter account constitute aggressive political marketing make invalid claims regarding performance competing vaccines pfizerbiontech anvisa said import ban reversed gamaleya clarifies issues adenovirus infections cause mild colds healthy individuals cause lifethreatening illnesses immunodeficient director public health institute chile isp heriberto garcia said isp would necessarily reject vaccine even replicating adenoviruses risk getting common cold vaccine must seen light risk contracting vaccinated also said realworld data argentina mexico showed adverse effects greater seen people vaccinated pfizerbiontech vaccine june anvisa approved exceptional imports sputnik v restricting mainly healthy adults limiting population importing states order manage risks control supervision side effects anvisa said concern replicating viruses fully resolved additional documents received indicate substantially reduced acceptable amount new parameter would fda manual found anvisa also said impurity quality controls insufficient manufacturing plants must undergo corrections meet quality june import conditions extended total august consortium northeastern brazilian states corresponding states suspended import million doses due restrictions imposed anvisa doses supply mexico argentina december russian direct investment fund rdif gamaleya national center astrazeneca rpharm signed agreement aimed development implementation clinical research program assess immunogenicity safety combined use one components sputnik v vaccine developed gamaleya center one components study program last months several countries planned involve volunteers study program february ministry health republic azerbaijan allowed clinical studies country combined use vaccine sputnik light stating trials would begin end february february official sputnik v twitter account stated clinical trials already vaccine free charge users russia kazakhstan cost per dose would less required two doses international markets much less cost mrna vaccines manufacturers kirill dmitriev head fund told reporters billion doses vaccine expected produced outside head gamaleya research institute alexander ginzburg estimated would take months vaccinate vast majority russian population assuming incountry resources commercial release gamcovidvac first scheduled september october mikhail murashko said gamcovidvac would free russian citizens launching mass later russian ministry health registered maximum exfactory price equal rubles two components included national list essential also suggestions include vaccine national immunisation calendar beginning december russian authorities announced start largescale free charge vaccination gamcovidvac russian citizens immunization program launched december medical centers moscow providing doctors medical workers teachers social workers given priority due highest risk exposure initially vaccine offered people years age later restriction potential recipients notified via text messaging said working educational institution toppriority vaccine free charge patients asked general health questions receiving people certain underlying health conditions pregnant women respiratory illness past two weeks barred vaccine vial removed medical centres freezer minutes use early december minister health mikhail murashko said russia already vaccinated highrisk forty thousand volunteers sputnik vs phase trials another nurses doctors also taken head russian direct investment fund kirill dmitriev said interview bbc russian medics expected give million people coronavirus vaccinations december beginning december generium supervised pharmstandard binnopharm supervised afk sistema companies produced gamcovidvac large scale december deputy prime minister tatyana golikova announced approximately million doses sputnik v vaccine would enter civilian circulation russia end february moscow mayor sergei sobyanin announced newly opened moscowbased rpharm become leading manufacturer russias sputnik v coronavirus vaccine working full capacity factory produce million doses may sergei sobyanin complained million moscow residents million received first dose russians received forbes russia established russia committed export millions doses sputnik v countries may millions far survey found russian population felt hesitant afraid getting sick willing wait june increase delta variant cases several russian city governments introduced strict measures overcome vaccine hesitancy requiring vaccine qr codes customers russia pursuing deals supply vaccine according russian direct investment fund received orders billion doses vaccine december countries made requests doses supplies global market produced partners india brazil china south korea hungary august according russian authorities least countries wanted obtain israeli hadassah medical center signed commercial memorandum understanding obtain million argentina agreed buy million doses russias vaccine subject clearing clinical vaccine registered approved argentina late december brazilian state bahia signed agreement conduct phase iii clinical trials sputnik v vaccine planned buy million doses market northeastern january argentine president alberto fernández became first latin american leader inoculated sputnik v shortly approved use two months vaccinated developed fever headache tested positive asymptomatic ten days later discharged medical treatment subject medical followup usual former patients resumed normal according new york times sources february israel agreed finance supply sputnik v vaccine syria order secure release israeli civilian held due delay shipping doses italy european union san marino imported doses sputnik v vaccine approved ema started mass vaccination february healthcare april armenia agreed russia purchase million doses coronavirus vaccines sputnik v decision armenian health minister anahit avanesyan armenian authorities begun negotiations russia production sputnik v coronavirus vaccine head armenian ministry health anahit avanesyan stated press conference march opinion poll canadians conducted léger august found majority would take russian vaccine offered free dose compared said would take americans asked question would take russian vaccine offered free dose compared said would take june according poll conducted ostausschuss der deutschen wirtschaft de german eastern business association majority germans would use russian vaccine sputnik v opportunity approval values east germany significantly higher respondents also solid majority west germany respondents hand would want use sputnik july opinion polls suggested around russian population doubts vaccine september dropped around half russian may levada center released poll respondents regions showed russians prepared vaccinated sputnik v prepared vaccinated ten percent respondents already resale arrangement russian direct investment fund rdif offered abu dhabibased firm aurugulf health investments exclusive rights sell sputnik v coronavirus vaccine according media reports vaccine intended sold host countries huge premiums per documents reviewed moscow times emirati sheikh ahmed dalmook almaktoum dubai royal worked middleman reselling millions sputnik v vaccine doses countries dire need vaccine higher premium corporate registry data showed one two entities controlling aurugulf royal group conglomerate headed uae national security advisor sheikh tahnoon bin zayed alnahyan acquired documents interviews officials buyer data showed countries like pakistan guyana receiving end vaccine uae coerced pay double price advertised deal used reselling million sputnik v vaccine doses emirati royal sheikh ahmed dalmook almaktoum kenya huge markups however deal eventually failed nairobi learnt first shipment consisting doses coming directly august world health organization spokesperson said prequalification vaccine includes rigorous review assessment required safety efficacy assistant director said use vaccine drugs medicines without following stages complied francois balloux geneticist university college london called russian governments approval gamcovidvac reckless foolish professor paul offit director vaccine education center childrens hospital philadelphia characterized announcement political stunt stated untested vaccine could stephen griffin associate professor school medicine university leeds said cautiously optimistic vaccines targeting spike protein effective moreover sputnik antigen delivered via different modality namely using disabled adenovirus rather formulated rna provides flexibility terms perhaps one method providing better responses certain agegroups ethnicities etc plus storage vaccine ought huge risk confidence vaccines would damaged vaccine received approval shown harmful said immunologist peter ian jones professor virology university reading polly roy professor chair virology london school hygiene tropical medicine commenting phase iii results published lancet february said development sputnik v vaccine criticised unseemly haste corner cutting absence transparency outcome reported clear scientific principle vaccination demonstrated means another vaccine join fight reduce incidence may group biostatisticians published article lancet data discrepancies substandard reporting interim data sputnik v phaseiii trial according article lack transparency trial results raises serious concerns data inconsistencies found including low probability homogeneity vaccine efficacy across age two preliminary studies one argentina one san marino found mostly mild adverse events vaccineassociated another study carried san marino concluded high tolerability profile population aged years terms shortterm adverse events following article published journal nature july cited data released united arab emirates individuals received sputnik v according vaccine demonstrated efficacy preventing symptomatic efficacy preventing severe complications figures echoed similar findings unpublished data million russians according sputnik v demonstrated efficacy study published journal medical internet research analyzed dataset consisted selfreported sputnik v vaccine adverse events posted telegram telegram users complained mostly pain fever fatigue